PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy November 26, 2019
PTC Therapeutics Announces Results from Gene Therapy Treatment Demonstrating Sustained Improvements October 25, 2019
PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna™ Slows Disease Progression in Patients with Duchenne Muscular Dystrophy October 9, 2019
PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics July 2, 2019
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age June 7, 2019
